Emeryville, California, August 17, 2026
Slingshot Bio, a developer of precision-engineered synthetic cell mimics for flow cytometry controls, has launched ViaComp® Ultra™ XT, a new single-vial cell mimic designed to combine compensation, spectral unmixing, and viability assessment in one product. The company describes ViaComp Ultra XT as the first cell mimic to integrate these three commonly used flow cytometry controls into a single product, with the goal of simplifying workflows and improving consistency in advanced cell analysis. The launch comes as spectral flow cytometry continues to support increasingly complex assay panels, with modern instruments capable of analyzing more than 40 colors. Slingshot Bio developed the product to address limitations associated with conventional polystyrene-based controls and variable biological reference materials, providing researchers with a synthetic hydrogel-based alternative designed to behave more like biological cells while maintaining reagent stability and reproducibility.
Single-Vial Design Simplifies Flow Cytometry Workflows
ViaComp Ultra XT combines multiple control functions that traditionally require separate materials. The product uses hydrogel cell mimics engineered to reproduce cell-like behavior within flow cytometers while providing the stability and consistency associated with synthetic reagents. According to Slingshot Bio, the cell mimics can bind fixable amine-reactive or DNA-intercalating viability dyes and capture fluorophore-conjugated antibodies used in spectral flow cytometry. The platform is designed to capture fluorescence signatures from antibodies associated with commonly used species, including mouse, rat, hamster, rabbit, and human antibodies. By bringing compensation, spectral unmixing, and viability assessment into one vial, the company aims to reduce preparation requirements and simplify the setup of increasingly complex flow cytometry panels. The product is supplied as a pre-mixed suspension containing positive and negative control particles designed to generate clearly separated peaks for fluorophores included in an assay panel.
Synthetic Cell Mimics Target Reproducibility Challenges
Slingshot Bio developed ViaComp Ultra XT in response to what it describes as limitations associated with both plastic-based controls and biological reference materials. The company states that polystyrene and other plastic-derived particles can behave differently from biological cells during spectral analysis and may not support viability-dye binding. Biological controls, meanwhile, can introduce variability because of their fragility and dependence on biological material. ViaComp Ultra XT is designed to bridge these limitations through precision-engineered synthetic cell mimics that reproduce relevant cell characteristics while offering greater stability. The product is manufactured to ISO 17025 reference material standards, according to the company, with the aim of supporting consistent quality and performance across different flow cytometry instruments. The control is also designed to eliminate the need for titration, preparation steps, or viability cultures, while remaining stable, non-hazardous, and stored at 4°C.
Advertisement
Flow Cytometry Technology Supports Biopharma Research
ViaComp Ultra XT is available in 25-test and 100-test sizes and is now shipping. Slingshot Bio said the product is intended to help research laboratories improve efficiency while reducing the complexity associated with preparing multiple controls for sophisticated flow cytometry assays. The technology has potential relevance across cell therapy, drug development, diagnostics, and flow cytometry instrument applications, where reliable cell-analysis controls are important for generating reproducible research data. For cGxP.wire readers, the launch is significant because advanced flow cytometry is increasingly used in life-sciences research and development, including applications that require detailed cellular characterization and multiparameter analysis. By combining viability assessment, antibody capture, compensation, and spectral unmixing in a single synthetic control, Slingshot Bio is targeting workflow efficiency and reproducibility challenges associated with increasingly complex cytometry experiments. The launch also demonstrates the continued development of specialized laboratory technologies designed to support biopharmaceutical research, cell-based studies, diagnostics, and analytical workflows. Slingshot Bio, founded in 2012 and headquartered in Emeryville, California, says thousands of flow cytometrists worldwide use its cell mimic products.
Source: Slingshot Bio press relese
